...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Re: Merck's PIII Prostate trial, not the one with ZEN-3694, is halted for not showing improvement vs control

As I understand it, the trial was stopped because it failed to meet its endpoint (or wasn't expected to) not because of the adverse effects. I guess all trials inherently have adverse effects. Perhaps ZEN-3694 will put them over the line. Time will tell. 

 

Koo (IMO)

Share
New Message
Please login to post a reply